AstraZeneca
AZN
1,211 hedge funds and large institutions have $39B invested in AstraZeneca in 2024 Q2 according to their latest regulatory filings, with 155 funds opening new positions, 504 increasing their positions, 331 reducing their positions, and 70 closing their positions.
121% more first-time investments, than exits
New positions opened: 155 | Existing positions closed: 70
58% more funds holding in top 10
Funds holding in top 10: 12 → 19 (+7)
52% more repeat investments, than reductions
Existing positions increased: 504 | Existing positions reduced: 331
49% more call options, than puts
Call options by funds: $500M | Put options by funds: $336M
15% more capital invested
Capital invested by funds: $33.8B → $39B (+$5.23B)
6% more funds holding
Funds holding: 1,141 → 1,211 (+70)
0.05% more ownership
Funds ownership: 16.06% → 16.11% (+0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$276M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$209M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$206M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$164M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$162M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$643M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$234M |
| 3 |
Holocene Advisors
New York
|
-$222M |
| 4 |
Millennium Management
New York
|
-$215M |
| 5 |
Morgan Stanley
New York
|
-$203M |
AZN Hedge Fund Activity: Q2 2024 in Review
1,211 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2024, worth a combined $39B — up 15% from $33.8B a quarter earlier.
Buyers outnumbered sellers: 155 funds opened new AZN positions and 70 closed out — a net gain of 85 holders — while 504 added to existing stakes and 331 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $276M. The largest seller was Wellington Management Group, cutting an estimated $643M.
- 1,211 institutional investors held AstraZeneca (AZN) as of Q2 2024, up from 1,141 in Q1 2024.
- Funds reported $39B of AstraZeneca stock for Q2 2024, up 15% quarter-over-quarter.
- 155 funds opened new AstraZeneca positions in Q2 2024 and 70 closed out, a net change of +85 holders.
- The largest AstraZeneca buyer in Q2 2024 was T. Rowe Price Associates, an estimated $276M added.
- The largest AstraZeneca seller in Q2 2024 was Wellington Management Group, an estimated $643M sold.
Based on aggregated 13F filings for Q2 2024.